"I would like to thank Peter for his dedicated support over the last year and a half, and his contribution to the success of Quotient. He has played an important role in supporting the execution of our company’s strategic vision. On behalf of the Board and the Company, I wish him success in his new endeavor," said Manuel O. Méndez, Chief Executive Officer of Quotient.
In accordance with Mr. Buhler’s employment agreement, unless the Company elects otherwise, his resignation will take effect on
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins,
Contact: IR@quotientbd.com; +41 22 545 52 26
Source: Quotient Limited